Video

Dr. Rogers on Determining Patients With High-Risk CLL

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses how to determine patients with high-risk chronic lymphocytic leukemia (CLL).

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses how to determine patients with high-risk chronic lymphocytic leukemia (CLL).

The patients need to have a high-risk cytogenetic feature that predicts shorter survival from CLL and a shorter time to needing treatment, explains Rogers. An example of a cytogenetic feature is 17p deletion.

According to Rogers, patients with lower-risk disease can go decades without needing treatment. However, a patient with high-risk CLL will need treatment in 1 to 2 years. A potential therapy for high-risk patients is the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) since it demonstrated an objective response rate (ORR) of 78% in the phase III GENUINE study. This trial also demonstrated that ublituximab in combination with ibrutinib yields superior ORR to ibrutinib alone, which was 45% in high-risk CLL.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity